Genetic predictors of medically refractory ulcerative colitis.
Inflamm. Bowel Dis., Nov;16(11):1830-40 (2010)
Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease.
Am. J. Gastroenterol., Jan;105(1):148-54 (2010)
Linkage of Crohn's disease-related serological phenotypes: NFKB1 haplotypes are associated with anti-CBir1 and ASCA, and show reduced NF-kappaB activation.
Gut., Jan;58(1):60-7 (2009)
Family history and serology predict Crohn's disease after ileal pouch-anal anastomosis for ulcerative colitis.
Dis. Colon Rectum., Jan;51(1):100-8 (2008)
Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis?
Dis. Colon Rectum., Nov;50(11):1747-53 (2007)
NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives.
Gastroenterology., Feb;132(2):576-86 (2007)
Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn's disease.
Gastroenterology., Apr;130(4):1078-85 (2006)
Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses.
Am. J. Gastroenterol., Aug;101(8):1834-40 (2006)
Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn.
Clin. Gastroenterol. Hepatol., Oct;4(10):1255-8 (2006)
A pilot study of adalimumab in infliximab-allergic patients.
Inflamm. Bowel Dis., Jul;10(4):333-8 (2004)
The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease.
Inflamm. Bowel Dis., Jul;10(4):352-6 (2004)
Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab.
Am. J. Gastroenterol., Jan;100(1):75-9 (2005)
Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease.
Am. J. Surg. Pathol., Sep;28(9):1204-11 (2004)
Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density.
Gut., Aug;53(8):1129-36 (2004)
High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy.
Clin. Gastroenterol. Hepatol., Apr;2(4):309-13 (2004)
Early nodular hyperplasia of the liver occurring with inflammatory bowel diseases in association with thioguanine therapy.
Arch. Pathol. Lab. Med., Jan;128(1):49-53 (2004)
Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease.
Gastroenterology., Feb;126(2):414-24 (2004)
Infliximab in the treatment of medically refractory indeterminate colitis.
Aliment. Pharmacol. Ther., Oct;18(7):741-7 (2003)
6-thioguanine can cause serious liver injury in inflammatory bowel disease patients.
Gastroenterology., Aug;125(2):298-303 (2003)
Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine.
Am. J. Gastroenterol., May;98(5):1058-63 (2003)
Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease.
Gastroenterology., Sep;123(3):679-88 (2002)
Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics.
Gut., Oct;47(4):487-96 (2000)
Outcome of cytomegalovirus infections in patients with inflammatory bowel disease.
Am. J. Gastroenterol., Jul;96(7):2137-42 (2001)
An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy.
Inflamm. Bowel Dis., Aug;7(3):181-9 (2001)
High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis.
Gut., Nov;49(5):671-7 (2001)
6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease.
Gastroenterology., Apr;122(4):904-15 (2002)
An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.
Gastroenterology., Dec;117(6):1278-87 (1999)
Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis.
Am. J. Gastroenterol., Aug;95(8):2000-8 (2000)
Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease.
Inflamm. Bowel Dis., Feb;6(1):16-20 (2000)
Colorectal cancer screening and surveillance in Crohn's colitis.
J Crohns Colitis., Sep;6(8):824-9 (2012)
Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism.
Aliment. Pharmacol. Ther., Sep;36(5):449-58 (2012)
Combination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn's disease.
Inflamm. Bowel Dis., Aug;16(8):1279-85 (2010)
Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease.
Inflamm. Bowel Dis., Dec;12(12):1122-30 (2006)